Clinical Analysis for Patients with AML Treated after Allo-HSCT / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1105-1114, 2020.
Article
em Zh
| WPRIM
| ID: wpr-827154
Biblioteca responsável:
WPRO
ABSTRACT
OBJECTIVE@#To analyze risk factors that affect survival and relapse of AML patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to investigate the therapy choices after AML relapse.@*METHODS@#Clinical data of 180 AML patients achieved complete remission (CR) before HSCT from January 2009 to December 2018 treated in our center were analyzed retrospectively. Risk factors for survival and relapse after allo-HSCT were analyzed by COX regression.@*RESULTS@#Among 180 AML patients, 134 survived (74.4%), 46 patients died (25.6%), and 40 patients relapsed (22.2%). The rate of overall survival (OS), event-free survival (EFS) and cumulative rate of relapse in 5-years was 74.3%、42.5% and 25.0%, respectively. High-risk, adverse cytogenetics, CR at HSCT and no cGvHD were independent risk factors that affect OS. CR at HSCT, high-risk were independent risk factors that affect EFS. High-risk, MRD after one course of induction therapy, adverse cytogenetics and no cGVHD were independent risk factors that affect relapse. The OS rate of relapse patients could be improved by the usage of hypomethylation agents combined with G-CSF mobilized donor lymphocyte infusion (DLI), and 2-year OS rate was 62.5%.@*CONCLUSION@#The survival rate of AML is greatly improved by allo-HSCT, but relapse is still one of the most important factors that influence survival of the AML patients. The maintenance therapy of hypomethylation agents combined with DLI may be a new effective treatment option for patients who relapse after HSCT.
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Indução de Remissão
/
Leucemia Mieloide Aguda
/
Estudos Retrospectivos
/
Transplante de Células-Tronco Hematopoéticas
/
Intervalo Livre de Doença
/
Recidiva Local de Neoplasia
Tipo de estudo:
Observational_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
Zh
Revista:
Journal of Experimental Hematology
Ano de publicação:
2020
Tipo de documento:
Article
País de publicação:
CHINA
/
CN
/
REPUBLIC OF CHINA